Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.40 USD
Change Today +0.17 / 0.26%
Volume 84.1K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

abaxis inc (ABAX) Key Developments

Abaxis, Inc. Presents at Sidoti & Company, LLC's 19th Annual Emerging Growth Research Institutional Investor Forum, Mar-17-2015 10:00 AM

Abaxis, Inc. Presents at Sidoti & Company, LLC's 19th Annual Emerging Growth Research Institutional Investor Forum, Mar-17-2015 10:00 AM. Venue: The Grand Hyatt Hotel, 109 E 42nd St., New York, NY 10017, United States. Speakers: Clinton H. Severson, Chairman, Chief Executive Officer and President.

Abaxis, Inc. Announces USDA Clearance of Vetscan Anaplasma Rapid Test

Abaxis, Inc. announced that the Center for Veterinary Biologicals of the U.S. Department of Agriculture (USDA) has cleared its VetScan Anaplasma Rapid Test Kit for the detection of A. phagocytophelium and A. platys in canine whole blood, serum, or plasma samples.

Abaxis, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 11:35 AM

Abaxis, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-04-2015 11:35 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States. Speakers: Clinton H. Severson, Chairman, Chief Executive Officer and President.

Abaxis, Inc. Declares Third Quarter Cash Dividend, Payable on March 17, 2015; Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Abaxis, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.10 per common share to be paid on March 17, 2015, to all shareholders of record as of the close of business on March 3, 2015. The company announced unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported revenues of $59.5 million, as compared with revenues of $40.8 million for the comparable period last year, an increase of 46%. The company reported net income of $5.9 million compared to $3.2 million for the fiscal quarter ended December 31, 2013. The company reported diluted net income per share of $0.26 compared to $0.14 per share for the same period last year. Income from operations was $9,156,000 against $4,623,000 a year ago. Income before income tax was $8,959,000 against $4,858,000 a year ago. For the nine-months, the company reported revenues of $160.9 million as compared with revenues of $129.8 million for the comparable period last year, an increase of 24%. The company reported net income of $16.0 million compared to $10.4 million for the same period last year. The company reported diluted net income per share of $0.70 for the nine-month period ended December 31, 2014, compared to $0.46 per share for the same period last year. Income from operations was $25,522,000 against $14,958,000 a year ago. Income before income tax Was $24,927,000 against $16,104,000 a year ago.

Abaxis, Inc. Announces U.S. Department of Agriculture Approval of VetScan FeLV-FIV Rapid Test Kit

Abaxis, Inc. announced that the Center for Veterinary Biologicals of the U.S. Department of Agriculture (USDA) has approved its VetScan FeLV-FIV Rapid Test Kit for the detection of FeLV antigen and FIV antibodies from feline blood samples. Feline Leukemia virus (FeLV) and the feline immunodefiency virus (FIV) are retroviruses found in cats, and are among the most common infectious diseases in this species. FeLV-FIV testing is one of the most common tests performed by veterinarians treating feline patients, and Abaxis is proud to offer another high quality, cost-effective test to the veterinary market.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABAX:US $64.40 USD +0.17

ABAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $134.95 USD +0.06
Heska Corp $25.46 USD +0.68
Millennium Healthcare Inc $0.08 USD -0.0039
PetMed Express Inc $16.18 USD +0.07
Trinity Biotech PLC $18.82 USD +0.46
View Industry Companies
 

Industry Analysis

ABAX

Industry Average

Valuation ABAX Industry Range
Price/Earnings 74.0x
Price/Sales 7.1x
Price/Book 7.0x
Price/Cash Flow 73.5x
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABAXIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.